Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC

Recruiting

Phase 2

Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC

Sponsor:

Pancreatic Cancer Research Team

Code:

NCT03634332

Conditions

Pancreatic Ductal Adenocarcinoma

Pancreatic Cancer

Pancreatic Neoplasms

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

PEGPH20

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-15. This information was provided to ClinicalTrials.gov by Pancreatic Cancer Research Team on 2019-05-07.